CancerDrs

Prostate Cancer clinical trials in Colorado

29 actively recruiting prostate cancer trials at 20 sites across Colorado.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full prostate cancer transparency page →

Phase 3 Recruiting Network

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in Colorado:
  • UCHealth University of Colorado Hospital — Aurora, Colorado
  • Penrose-Saint Francis Healthcare — Colorado Springs, Colorado
  • Rocky Mountain Cancer Centers-Penrose — Colorado Springs, Colorado
  • UCHealth Memorial Hospital Central — Colorado Springs, Colorado
  • Memorial Hospital North — Colorado Springs, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation ther…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04423211
Sites in Colorado:
  • Rocky Mountain Cancer Centers-Aurora — Aurora, Colorado
  • Rocky Mountain Cancer Centers-Boulder — Boulder, Colorado
  • Penrose-Saint Francis Healthcare — Colorado Springs, Colorado
  • Rocky Mountain Cancer Centers-Penrose — Colorado Springs, Colorado
  • Saint Francis Cancer Center — Colorado Springs, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in Colorado:
  • University of Colorado Hospital — Aurora, Colorado
  • Rocky Mountain Cancer Centers-Boulder — Boulder, Colorado
  • UCHealth Memorial Hospital Central — Colorado Springs, Colorado
  • Memorial Hospital North — Colorado Springs, Colorado
  • Porter Adventist Hospital — Denver, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

This randomized phase III trial examines whether lengthening the dosage interval in an adaptive manner for the prostate cancer drug lutetium 177 Lu PSMA RLT improves quality of life without decreasing lifespan when compared to the standard…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07200830
Sites in Colorado:
  • UCHealth University of Colorado Hospital — Aurora, Colorado
  • UCHealth Memorial Hospital Central — Colorado Springs, Colorado
  • Memorial Hospital North — Colorado Springs, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

The purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRP…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136650
Sites in Colorado:
  • University of Colorado Anschutz Medical Campus ( Site 0046) — Aurora, Colorado
  • UCHealth Highlands Ranch Hospital ( Site 0111) — Highlands Ranch, Colorado
  • Colorado Clinical Research ( Site 0067) — Lakewood, Colorado
  • University of Colorado Health - Lone Tree Medical Center ( Site 0112) — Lone Tree, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in Part 1 in combination with best supportive care (BSC) and in Part 2 wit…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07164443
Sites in Colorado:
  • Rocky Mountain Cancer Centers — Aurora, Colorado
  • University of Colorado Cancer Center — Aurora, Colorado
  • Colorado Clinical Research — Lakewood, Colorado
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \[177Lu\]Lu-PSMA ta…

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06780670
Sites in Colorado:
  • Rocky Mountain Cancer Centers — Denver, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

This study will test whether BNT324 is safe and works better against metastatic castration-resistant prostate cancer (mCRPC) than the current standard of care (SoC) chemotherapy, which is docetaxel (given together with the steroid medicine…

Sponsor: BioNTech SE
NCT ID: NCT07365995
Sites in Colorado:
  • Rocky Mountain Cancer Centers — Aurora, Colorado
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

This phase II trial tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation. Carboplatin is in a class of medications known as platinum-containing co…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05806515
Sites in Colorado:
  • Penrose-Saint Francis Healthcare — Colorado Springs, Colorado
  • Rocky Mountain Cancer Centers-Penrose — Colorado Springs, Colorado
  • Saint Francis Cancer Center — Colorado Springs, Colorado
  • Porter Adventist Hospital — Denver, Colorado
  • Mercy Medical Center — Durango, Colorado
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

FOG-001 in Locally Advanced or Metastatic Solid Tumors

The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Sites in Colorado:
  • University of Colorado — Aurora, Colorado
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug\[s\]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab. The study has…

Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT03972657
Sites in Colorado:
  • Sarah Cannon Research Institute (SCRI) — Denver, Colorado
View on ClinicalTrials.gov →
Phase 2 Recruiting Federal

High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers

This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermittent high dose testosterone. This therap…

Sponsor: VA Office of Research and Development
NCT ID: NCT05011383
Sites in Colorado:
  • Rocky Mountain Regional VA Medical Center, Aurora, CO — Aurora, Colorado
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer

Assessment of the safety and efficacy of HLD-0915 (JNJ-101556143) in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06800313
Sites in Colorado:
  • Rocky Mountain Cancer Center — Colorado Springs, Colorado
  • Sarah Cannon Research Institute 1 — Denver, Colorado
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Study of Oral MRT-2359 With Apalutamide in Prostate Cancer

This Phase 2, open-label, multicenter study is conducted in patients with castration-resistant prostate cancer. Patients in this study receive MRT-2359, an investigational oral medicine, in combination with apalutamide, an oral medicine us…

Sponsor: Monte Rosa Therapeutics, Inc
NCT ID: NCT07745361
Sites in Colorado:
  • Rocky Mountain Cancer Center — Colorado Springs, Colorado
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

This is a two-part, Phase I/II, open-label, global, multicenter study assessing the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) versus standard of care in participants with progressive meta…

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT07206056
Sites in Colorado:
  • Sarah Cannon Research Institute — Denver, Colorado
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

Phase 2a, open-label, multi-center study evaluating biomarkers and biodistribution of aglatimagene besadenovec plus valacyclovir in men with localized, intermediate-risk prostate cancer who are planning to receive external beam radiation t…

Sponsor: Candel Therapeutics, Inc.
NCT ID: NCT07332000
Sites in Colorado:
  • Colorado Clinical Research — Lakewood, Colorado
  • Urology Associates — Littleton, Colorado
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Telehealth Exercise Program Evaluating Fatigue and Physical Function in Rural Cancer Survivors

This study investigates the efficacy of a telehealth exercise program designed specifically for rural cancer survivors with cancer-related fatigue (CRF). Small dried blood samples and measures of physical function will be collected through…

Sponsor: University of Colorado, Denver
NCT ID: NCT07001241
Sites in Colorado:
  • University of Colorado Anschutz Medical Campus — Aurora, Colorado
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…

Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Colorado:
  • Exelixis Clinical Site #87 — Littleton, Colorado
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects with locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Neoplasms

Sponsor: SystImmune Inc.
NCT ID: NCT07080242
Sites in Colorado:
  • University of Colorado - Anschutz Cancer Pavilion — Aurora, Colorado
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase…

Sponsor: Eli Lilly and Company
NCT ID: NCT06465069
Sites in Colorado:
  • Sarah Cannon Research Institute at HealthOne — Denver, Colorado
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer

The primary objective of this trial is to determine the safety profile of xaluritamig at the proposed regimen in adult participants with metastatic castration-resistant prostate cancer (mCRPC).

Sponsor: Amgen
NCT ID: NCT07493512
Sites in Colorado:
  • Rocky Mountain Cancer Centers — Denver, Colorado
  • United States Oncology Regulatory Affairs Corporate Office — Denver, Colorado
  • US Oncology Research Investigational Products Center — Denver, Colorado
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

The purpose of Parts 1, 2A, and 2B of the study is to determine the recommended regimen for Phase 2 (RP2Rs) of combination of JNJ-87189401 with JNJ-78278343 and the purpose of Part 2C of this study is to determine how safe the RP2R(s) of t…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06095089
Sites in Colorado:
  • University of Colorado Anschutz Medical Campus — Aurora, Colorado
View on ClinicalTrials.gov →

Showing 25 of 29 trials with sites in Colorado. See all prostate cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-19